AI-generated summary
The authors report a phase III randomized, triple-blinded trial in breast cancer patients receiving doxorubicin-cyclophosphamide, comparing red plus infrared laser photobiomodulation with red-only or infrared-only protocols for chemotherapy-induced taste changes. They conclude that the red-only and infrared-only protocols were inferior to the combined red plus infrared protocol. Results also included weight gain and salivary flow differences between groups.
- Who or what was studied
- Women with breast cancer treated with doxorubicin-cyclophosphamide chemotherapy, randomized into three groups of 60
- Limits stated in the abstract
- The abstract does not state how the non-inferiority margin was defined, and the trial's outcomes include multiple secondary measures without stated adjustment for multiple comparisons.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Total energy
- 2 J, 3 J
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Laser, Visual analogue scale, Placebo-controlled, Trial registration. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.